Anaconda Biomed has announced that the European Patent Office has granted the company a European patent for “A device and a thrombectomy apparatus for extraction of thrombus from a blood vessel”, published as patent number EP 3866708 B1 on 27 September 2023. In addition, patent number US 11,771,446 B2 was also granted to the company on 3 October 2023 for a method to improve the efficacy of removing cerebral vascular thrombi.
The newly granted patents join a list of 17 issued patents for Anaconda, including “Thrombectomy device and system for extraction of vascular thrombi from a blood vessel” in the USA with patent number US 11,013,523 B2, among other key territories, such as recently granted ones in Canada and South Korea, as well as Japan, China, Brazil, Taiwan and Australia.
The company’s growing patent portfolio demonstrates its dedication to innovation and unwavering mission to “revolutionise stroke treatment worldwide”, as per a recent press release.
“Every year, approximately 15 million people globally suffer from stroke,” said Richard Ferrari, Anaconda chairperson. “With these recent achievements, we are one step closer to offering our neurovascular recanalisation technology to effectively treat these patients, minimising death and disabilities, and improving the quality of life for patients and their families.”
The focal point of Anaconda’s product portfolio is the ANA5 advanced neurovascular access thrombectomy device, which is specifically designed for use in the anterior and posterior neurovascular vessels—including the internal carotid artery, the M1 and M2 segments of the middle cerebral artery, the basilar artery, the posterior cerebral artery, and the vertebral arteries. ANA5 comprises an aspiration funnel catheter featuring variable stiffness sections to be used in conjunction with a stent retriever. The funnel catheter consists of a radiopaque nitinol braid covered with a silicone coating to enable local flow restriction.
According to Anaconda, ANA5 is currently an investigational device, and is not available for sale in the USA or the European Union.